Study of the Proteome and Cytokines During Inflammatory Syndromes of Different Etiologies.

Inflammatory Disease Clinical Trial

— Proteome  

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01903642
• Other study ID #: Bonnotte PHRC IR 2008
• Status: Terminated
• Phase: N/A
• First received: July 17, 2013
• Last updated: July 17, 2013
• Start date: March 2010
• Est. completion date: February 2012

Study information

• Verified date: July 2013
• Source: Centre Hospitalier Universitaire Dijon
• Contact: n/a
• Is FDA regulated: No
• Health authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
• Study type: Interventional

Clinical Trial Summary

The hypotheses of our research are based on the fact that various pathological states, infection, cancer, inflammatory disease, can induce an inflammatory syndrome, through different pathways, even though the clinical presentation can be identical. The identification of biological markers specific to an etiology would therefore allow a faster diagnosis and improve care for patients. We thus took an interest in the three groups of diseases most frequently responsible for an inflammatory syndrome, infections, cancers and auto-immune diseases. To achieve this, various methods will be used.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 97
• Est. completion date: February 2012
• Est. primary completion date: January 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

Patients presenting an inflammatory syndrome, defined by elevated C-reactive protein (CRP>50mg/L), whose etiology is related to infection, cancer or an inflammatory disease.

• Patients not on treatment (corticoids, immunosuppressive drugs) during the 7 days preceding inclusion

• Age: 18-90 years

• Patients covered by the National Health Insurance Agency

• signed written informed consent form

Exclusion Criteria:

• - Any patient not meeting the inclusion criteria

• Pregnant patients

Study Design

Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label

Related Conditions & MeSH terms

• Inflammatory Disease

Intervention

Other:
• proteomic analysis

Locations

Country	Name	City	State
France	CHU de Dijon	Dijon

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire Dijon

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	determination of usual parameters of inflammation		at baseline	No